. 2020 Jan 8;21:10. doi: 10.1186/s12931-020-1273-x

Table 1.

Baseline characteristics of 97 patients with Mycobacterium avium complex pulmonary disease and cavitary lesions

Characteristic	Progressive cavity Group (n = 52)	Non-progressive cavity Group (n = 45)	P value
Female	42 (80.8)	38 (84.4)	0.790
Age, years	68 (54–83)	63 (51–78)	< 0.001
Body mass index, kg/m^2a	16.7 (12.3–24.6)	18.3 (13.7–25.4)	0.043
Underlying lung disease
Pulmonary emphysema/bulla	5 (9.6)	3 (6.7)	0.721
Old pulmonary tuberculosis	8 (15.4)	4 (8.9)	0.373
Bronchiectasis	50 (96.2)	43 (95.6)	> 0.999
Interstitial pneumonia	4 (7.7)	2 (4.4)	0.683
Comorbidity
Chronic heart disease	15 (28.8)	14 (31.1)	0.828
Diabetes mellitus	11 (21.2)	1 (2.2)	0.005
Chronic liver disease	3 (5.8)	3 (6.7)	> 0.999
Collagen disease	3 (5.8)	2 (4.4)	> 0.999
Cerebrovascular disease	3 (5.8)	1 (2.2)	0.621
Postgastrointestinal tract surgery	3 (5.8)	3 (6.7)	> 0.999
Steroid and/or immunosuppressive agent use^b	3 (5.9)	2 (4.4)	> 0.999
MAC species^c
Mycobacterium avium	28 (54.9)	28 (62.2)	0.536
Mycobacterium intracellulare	21 (41.2)	13 (28.9)
Both	2 (3.9)	4 (8.9)
Sputum-smear positive^d	28 (66.7)	19 (46.3)	0.078
Treatment
No treatment	4 (7.7)	8 (17.8)
Non-CAM/AZM-included regimen	4 (7.7)	3 (6.7)
Multidrug regimen^e	41 (78.8)	34 (75.6)	0.809

Data are presented as median (range) or no. (%) of patients. AZM Azithromycin, CAM Clarithromycin, MAC Mycobacterium avium complex. ^a: Body mass index was checked for 38 and 37 patients. ^b: Steroid and/or immunosuppressive agent use was checked for 51 patients in the progressive cavity group. ^c: MAC species was checked for 51 patients in the progressive cavity group. ^d: Sputum-smear positivity was checked for 42 and 41 patients. ^e: Multidrug regimen refers to CAM/AZM-containing regimen with two or more drugs for at least 1 year. p < 0.05 was considered significant